 |
|
|
| |
Progression and risk factors after treatment with tenofovir
or entecavir for chronic hepatitis B based on a multistate modeling approach
|
| |
| |
EASL 2024 June 5-8 Milan Italy
Speaker in Q&A said there was no difference in mortality, question was in context that TDF lowers lipids or does not increase lipids so it might have better CVD profile.
|
| |
|
|
|
|
|
